×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
200
500
All
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Eli Lilly's Tirzepatide Shows Promise in Phase 3 Trial for Heart Failure and Obesity
FDA Approves Lilly's Tirzepatide for Obesity
GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity
Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
Understanding and Addressing the Stigma Faced by People with Type 2 Diabetes and Obesity
Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
Articles
Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
A More Human View of Glucose: How Hourly Visualizations Reduce Anxiety and Reveal Real Patterns
Wegovy Will Not Go OTC: What the Sources Actually Say
Bridging Data and Healthcare in the Nordics
How Well Do My CGM and BGM Readings Match?
Epigenetic Clues to Heart Risk in Type 2 Diabetes
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
Why mRNAs Are a Good Option for Vaccines
Why I Took Medical Courses to Strengthen My Data Skills
New Research Reveals the Hidden Complexity of Insulin Resistance
What the 2025 Diabetes Care Updates Mean for You
How an Hour-by-Hour View Transforms Time in Range Insights
Successfully Completed: Diabetes – A Global Challenge
Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
News
January 2026
Wegovy Oral Pill Launches in United States
December 2025
FDA Approves First Oral GLP-1 for Chronic Weight Management
Retatrutide Delivers Phase 3 Success and Signals Lilly’s Strategic Positioning
November 2025
Novo Nordisk Seeks FDA Approval for Higher 7.2 mg Dose of Wegovy
Novo Nordisk Reports Strong Phase 2 Results for Amycretin in Type 2 Diabetes
Oral Semaglutide Does Not Slow Alzheimer’s Progression: How Today’s Results Fit the Larger Story
Zealand Pharma Pauses Development of Dapiglutide
October 2025
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Top Subjects
Type 2 Diabetes
Obesity Treatment
Semaglutide
Novo Nordisk
Wegovy
GLP-1
Eli Lilly
Tirzepatide
Continuous Glucose Monitoring
Oral Semaglutide
Clinical Trial Results
Ozempic
FDA Approval
Zepbound
GLP-1 Therapy
GLP-1 Medicines
Drug Regulation
Medication Safety
EVOKE Trials
Alzheimer’s Disease
Oral GLP-1 Therapy
Time in Range
Diabetes
Clinical Trials
Glucose Patterns
Diabetes Data Visualization
Emotional Impact of CGM
Obesity
Diabetes Management
Cardiovascular Health
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
